OLEMA PHARMACEUTICALS, INC. APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition
OLEMA PHARMACEUTICALS, INC. (OLMA) reported APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition of $17.59 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Shareholders' Equity › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition · last filed 2026-03-16
- OLEMA PHARMACEUTICALS, INC. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2025-03-31 was $183.00K, a 10.73% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2024-12-31 was $132.00K, a 9.09% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2024-09-30 was $54.00K, a 37.21% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2024-06-30 was $182.00K, a 40.00% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2025 was $17.59M, a 2969.11% increase from fiscal 2024.
- OLEMA PHARMACEUTICALS, INC. apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2024 was $573.00K, a 26.77% increase from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2023 was $452.00K, a 20.21% increase from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2022 was $376.00K, a 61.37% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2025-12-31 | $17.59M 10-K · filed 2026-03-16 | |||
| 2025-03-31 | $183.00K 10-Q · filed 2025-05-13 | $315.00K derived: sum of 2 quarters · filed 2026-03-16 | $369.00K derived: sum of 3 quarters · filed 2026-03-16 | $551.00K derived: sum of 4 quarters · filed 2026-03-16 |
| 2024-12-31 | $132.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $186.00K derived: sum of 2 quarters · filed 2026-03-16 | $368.00K derived: sum of 3 quarters · filed 2026-03-16 | $573.00K 10-K · filed 2026-03-16 |
| 2024-09-30 | $54.00K 10-Q · filed 2025-11-10 | $236.00K derived: sum of 2 quarters · filed 2025-11-10 | $441.00K 10-Q · filed 2025-11-10 | $562.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $182.00K 10-Q · filed 2025-08-11 | $387.00K 10-Q · filed 2025-08-11 | $508.00K derived: sum of 3 quarters · filed 2025-08-11 | $594.00K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $205.00K 10-Q · filed 2025-05-13 | $326.00K derived: sum of 2 quarters · filed 2025-05-13 | $412.00K derived: sum of 3 quarters · filed 2025-05-13 | $542.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $121.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $207.00K derived: sum of 2 quarters · filed 2025-03-18 | $337.00K derived: sum of 3 quarters · filed 2025-03-18 | $452.00K 10-K · filed 2025-03-18 |
| 2023-09-30 | $86.00K 10-Q · filed 2024-11-12 | $216.00K derived: sum of 2 quarters · filed 2024-11-12 | $331.00K 10-Q · filed 2024-11-12 | $443.00K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $130.00K 10-Q · filed 2024-08-06 | $245.00K 10-Q · filed 2024-08-06 | $357.00K derived: sum of 3 quarters · filed 2024-08-06 | $425.00K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $115.00K 10-Q · filed 2024-05-08 | $227.00K derived: sum of 2 quarters · filed 2024-05-08 | $295.00K derived: sum of 3 quarters · filed 2024-05-08 | $400.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $112.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $180.00K derived: sum of 2 quarters · filed 2024-03-11 | $285.00K derived: sum of 3 quarters · filed 2024-03-11 | $376.00K 10-K · filed 2024-03-11 |
| 2022-09-30 | $68.00K 10-Q · filed 2023-11-07 | $173.00K derived: sum of 2 quarters · filed 2023-11-07 | $264.00K 10-Q · filed 2023-11-07 | $351.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $105.00K 10-Q · filed 2023-08-08 | $196.00K 10-Q · filed 2023-08-08 | $283.00K derived: sum of 3 quarters · filed 2023-08-08 | $315.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $91.00K 10-Q · filed 2023-05-09 | $178.00K derived: sum of 2 quarters · filed 2023-05-09 | $210.00K derived: sum of 3 quarters · filed 2023-05-09 | $260.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $87.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $119.00K derived: sum of 2 quarters · filed 2023-03-09 | $169.00K derived: sum of 3 quarters · filed 2023-03-09 | $233.00K 10-K · filed 2023-03-09 |
| 2021-09-30 | $32.00K 10-Q · filed 2022-11-08 | $82.00K derived: sum of 2 quarters · filed 2022-11-08 | $146.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $50.00K 10-Q · filed 2022-08-09 | $114.00K 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $64.00K 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $30.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |